Insight

Photo of Hannah Goulart taken from www.researchgate.net

Jun 12, 2024, 15:23

Naveen Pemmaraju: Delighted to share our brand new review paper led by Dr Hannah Goulart

Naveen Pemmaraju recently shared a post on X:

“Delighted to share our brand new review paper at the British Journal of Haematology led by Dr Hannah Goulart.”

Read further
Source: Naveen Pemmaraju/X

Naveen Pemmaraju is a Professor and Director of the BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC) and Executive Director of the MDACC Network. He is also the Leukemia Hematology/Oncology Course Director.

His research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), MPN and AML.

AYACSM British Journal of Haematology cancer Claire Harrison Hannah Goulart Jean-Jacques Kiladjian Lucia Masarova MPNSM myeloproliferative neoplasms Naveen Pemmaraju OncoDaily Oncology Ruben Mesa

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage